---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-24-000054"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:47:12.422689+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics expands Newsoara license globally for $20M upfront, up to $96M milestones

## Summary
- Second Amendment to License Agreement with Newsoara Biopharma expands original China license to global.
- Newsoara to pay $20M upfront within one year; if not paid, amendment void.
- Up to $41M in development milestones and $35M in sales milestones, plus mid-to-upper single-digit royalties.
- vTv Therapeutics LLC (subsidiary of vTv Therapeutics Inc.) is the licensor.

## SEC filing metadata
- accession: 0001641489-24-000054
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000054/0001641489-24-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000054/vtvt-20240626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-24-000054
- JSON: https://secwatch.observer/filing/0001641489-24-000054.json
- Plain text: https://secwatch.observer/filing/0001641489-24-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.